US 11,945,851 B2
MAGE-A vaccines and methods of treatment using the same
David Weiner, Merion, PA (US); and Elizabeth Duperret, Philadelphia, PA (US)
Assigned to The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
Appl. No. 16/619,500
Filed by The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
PCT Filed Jun. 7, 2018, PCT No. PCT/US2018/036417
§ 371(c)(1), (2) Date Dec. 5, 2019,
PCT Pub. No. WO2018/226931, PCT Pub. Date Dec. 13, 2018.
Claims priority of provisional application 62/516,607, filed on Jun. 7, 2017.
Prior Publication US 2020/0140508 A1, May 7, 2020
Int. Cl. C07K 14/47 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07K 14/4748 (2013.01) [A61K 39/001186 (2018.08); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/53 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55533 (2013.01); A61K 2039/572 (2013.01); A61K 2039/86 (2018.08); A61K 2039/876 (2018.08)] 17 Claims
 
1. An immunological composition comprising a nucleotide sequence encoding a consensus MAGE-A antigen, wherein the consensus MAGE-A antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, an amino acid sequence comprising the amino acid residues 19-333 of SEQ ID NO:3, an amino acid sequence comprising the amino acid residues 19-335 SEQ ID NO:7, and an amino acid sequence comprising the amino acid residues 19-338 of SEQ ID NO:11.